Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
about
Current Trends of Renal Impairment in Multiple MyelomaInternational Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationCarfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factorsAdvances in understanding prognosis in myeloma.Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.Chronic kidney disease stage 5 as the prognostic complement of International Staging System for multiple myeloma.Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safetyPhase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myelomaExpert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myelomaLenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment.Oliguria as an early indicator of mortality risk in patients with multiple myeloma and renal impairment.Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide.Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.Pathogenesis of renal failure in multiple myeloma: any role of contrast media?The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment.Case report on renal failure reversal in lambda chain multiple myeloma with bortezomib and dexamethasone.Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality.Percentage of urinary albumin excretion and serum-free light-chain reduction are important determinants of renal response in myeloma patients with moderate to severe renal impairment.Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.Proton NMR-based metabolite analyses of archived serial paired serum and urine samples from myeloma patients at different stages of disease activity identifies acetylcarnitine as a novel marker of active disease.Chronic diarrhea as the presenting feature of primary systemic AL amyloidosis: serendipity or delayed diagnosis?Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma.Multiple myeloma presenting as acute renal failureSwitching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma.Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity scoreRedeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain productionInternational Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.Daily postdilutional hemodiafiltration with FX800 polysulfone dialyzers for removing kappa light chains in multiple myeloma-induced kidney injuryA case of multiple myeloma presenting as a distal renal tubular acidosis with extensive bilateral nephrolithiasis.European perspective on multiple myeloma treatment strategies: update following recent congressesTherapeutic Efficacy and Cost Effectiveness of High Cut-Off Dialyzers Compared to Conventional Dialysis in Patients with Cast Nephropathy.European Myeloma Network guidelines for the management of multiple myeloma-related complications.Renal complications in multiple myeloma and related disorders: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma
P2860
Q26740444-5C30C756-72F5-411C-BC01-5471B56E47A5Q27002668-A5D8EAC6-D801-4334-8A4E-3FA535BD3336Q28084683-492C015C-D1A1-4AF6-A637-EA331A309430Q30244061-5541BE1A-83ED-4794-946E-535B98808116Q30595175-DDB9B9BC-043F-46CC-98E1-CE7FB8DD134AQ33397490-7C19099F-3358-410F-8A1B-C09DA10C0E9FQ33398587-B418554C-7275-4EAE-9B6F-C9A179145FFAQ33400871-9E136052-5100-4ABE-B695-395FB08E405CQ33405602-CBA7DB6A-9D88-48BE-B8FA-7DB7BAF4FD05Q33408056-91643A81-E1D1-4602-AA3B-564E840FB0E3Q33413142-80F62525-041C-455A-93BB-F6ECD42FB7AEQ33421008-2B79F8C7-DECF-4753-8A6A-C25D6BFF2D9BQ33426615-0318BECA-3CFF-450E-A1CB-7FB9877BAAE8Q33433453-56C7C80A-EDCD-429F-905A-1643D945F0A5Q33442039-9A505C9C-2994-4C80-B476-5732A07050DEQ33558161-42AB1E25-DB6C-439C-9151-71601D71DD63Q33616884-07D63587-F9A6-4967-8F8F-964689F7E358Q33864162-1114B03B-FF7F-4DAB-8FB7-75C669DDDCD5Q33874209-C93C0E07-DFDE-4C14-8D44-B6B59F03570AQ34362184-554ACD97-0753-426E-9E1D-C6EE8BD35214Q34448964-6DF984BB-468F-4FCF-AE06-ECA9C0516057Q34539519-5DAEB9B3-86B7-4F49-9B37-5E42D361E4E2Q34595084-889C4A36-814E-44A0-80BF-1825D4B830B4Q34687304-F2794044-A1A2-45E4-BD56-C6E73F4201A9Q34788381-077B06C7-5A96-4F8F-B32B-E7C14A6A343DQ35244883-970C6F0C-FAF9-4CB9-A0D5-4DE568238FA0Q35488351-A8B2B5F5-EA7B-46AF-B7E0-C1BE753AD0B3Q35557435-9FC7F28B-2C07-47CF-8079-772A16983D7BQ35603608-80801C67-47EC-4B15-8700-DDD371137C97Q35664302-D6840E3B-E4ED-4FFB-8532-D05A879E1CE3Q35664315-BA61AC5A-9D37-4DAF-A855-BC9EA59D2C3EQ35802414-047BBA76-5304-4E19-8107-E5BC20212618Q35830287-397C59ED-A5CA-4497-8826-7425C982C2B0Q35964482-58583603-12A7-4A7E-A6B3-A127FF6B6CD2Q35989943-FE577DF7-CD77-4AD1-9B29-C3CEAFD7173BQ36088601-370AE4D7-E4BB-409E-A0CC-CA806DBC408AQ36115636-BE868B5D-074F-407C-95C3-FE488AE16EB9Q36209159-1E54C923-E873-4772-8C89-A0DC6512AE7CQ36307049-5254F21F-F0C3-46F2-B5D7-288D5F3D684CQ36750472-B8EF94A8-0CE0-4B00-9352-F1F83B0D7FDE
P2860
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Renal impairment in patients w ...... ational Myeloma Working Group.
@en
Renal impairment in patients w ...... ational Myeloma Working Group.
@nl
type
label
Renal impairment in patients w ...... ational Myeloma Working Group.
@en
Renal impairment in patients w ...... ational Myeloma Working Group.
@nl
prefLabel
Renal impairment in patients w ...... ational Myeloma Working Group.
@en
Renal impairment in patients w ...... ational Myeloma Working Group.
@nl
P2093
P50
P356
P1476
Renal impairment in patients w ...... ational Myeloma Working Group.
@en
P2093
Asher Chanan-Khan
Brian G M Durie
Evangelos Terpos
Jean-Luc Harousseau
Jean-Paul Fermand
Joan Bladé
Orhan Sezer
Patrizia Tosi
Raymond L Comenzo
Sundar Jagannath
P304
P356
10.1200/JCO.2010.30.8791
P407
P50
P577
2010-10-18T00:00:00Z